Personalized medicine: The road ahead

Clinical Breast Cancer

Volumn 11, Issue 1, 2011, Pages 20-26

  Mehta, Rutika ^a   Jain, Rohit ^a   Badve, Sunil ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Future directions; Prognostic factors

Indexed keywords

ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MICRORNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; TAXANE DERIVATIVE;

BREAST CANCER; CANCER CLASSIFICATION; DNA REPAIR; PHARMACOGENOMICS; PROGNOSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STEM CELL TRANSPLANTATION; TUMOR VOLUME;

EID: 79953792732     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.3816/CBC.2011.n.004     Document Type: Review

References (88)

1. Elston CW, Ellis IO, Pinder SE. Pathological prognostic factors in breast cancer. Crit Rev Oncol Hematol 1999; 31:209-23. (Pubitemid 29424143)
2. Clark GM. Diseases of the breast. Philadelphia, P.A.: Lippincott-Raven; 2004.
3. Hilsenbeck SG, Ravdin PM, de Moor CA, et al. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 1998; 52:227-37. (Pubitemid 29056098)
4. Fisher B, Dignam J, Tan-Chiu E, et al. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst 2001; 93:112-20. (Pubitemid 32111988)
5. Rosen PP, Groshen S, Saigo PE, et al. Pathological prognostic factors in stage i (t1n0m0) and stage ii (t1n1m0) breast carcinoma: A study of 644 patients with median follow-up of 18 years. J Clin Oncol 1989; 7:1239-51. (Pubitemid 19220125)
6. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of american pathologists consensus statement 1999. Arch Pathol Lab Med 2000; 124:966-78.
7. Fisher ER, Anderson S, Redmond C, et al. Pathologic findings from the national surgical adjuvant breast project protocol b-06. 10-year pathologic and clinical prognostic discriminants. Cancer 1993; 71:2507-14. (Pubitemid 23100484)
8. Russo J, Frederick J, Ownby HE, et al. Predictors of recurrence and survival of patients with breast cancer. Am J Clin Pathol 1987; 88:123-31. (Pubitemid 17137861)
9. Smith JA, 3rd, Gamez-Araujo JJ, Gallager HS, et al. Carcinoma of the breast: Analysis of total lymph node involvement versus level of metastasis. Cancer 1977; 39:527-32. (Pubitemid 8063513)
10. Pereira H, Pinder SE, Sibbering DM, et al. Pathological prognostic factors in breast cancer. Iv: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology 1995; 27:219-26.
11. Henson DE, Ries L, Freedman LS, et al. Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer 1991; 68:2142-9.
12. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11:359-77.
13. Le Doussal V, Tubiana-Hulin M, Friedman S, et al. Prognostic value of histologic grade nuclear components of scarff-bloom-richardson (sbr). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 1989; 64:1914-21. (Pubitemid 19267813)
14. Neville AM, Bettelheim R, Gelber RD, et al. Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The international (ludwig) breast cancer study group. J Clin Oncol 1992; 10:696-705.
15. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifentreated, node-negative breast cancer. N Engl J Med 2004; 351:2817-26. (Pubitemid 40051905)
16. Jensen EV. On the mechanism of estrogen action. Perspect Biol Med 1962; 6:47-59.
17. Beatson G. On the treatment of inoperable cases of carcinoma of the mamma. Lancet 1896; 2:104-7.
18. Knight WA, Livingston RB, Gregory EJ, et al. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 1977; 37:4669-71. (Pubitemid 8239679)
19. Pertschuk LP, Feldman JG, Kim YD, et al. Estrogen receptor immunocytochemistry in paraffin embedded tissues with er1d5 predicts breast cancer endocrine response more accurately than h222sp gamma in frozen sections or cytosol-based ligand-binding assays. Cancer 1996; 77:2514-9.
20. Rhodes A, Jasani B, Balaton AJ, et al. Immunohistochemical demonstration of oestrogen and progesterone receptors: Correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J Clin Pathol 2000; 53:292-301. (Pubitemid 30180402)
21. Hammond ME, Hayes DF, Dowsett M, et al. American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;
22. Badve SS, Baehner FL, Gray RP, et al. Estrogen- and progesterone-receptor status in ecog 2197: Comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 2008; 26:2473-81.
23. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17:1474-81. (Pubitemid 29220854)
24. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: Correlation of relapse and survival with amplification of the her-2/neu oncogene. Science 1987; 235:177-82. (Pubitemid 17231334)
25. Hayes DF, Thor AD. C-erbb-2 in breast cancer: Development of a clinically useful marker. Semin Oncol 2002; 29:231-45. (Pubitemid 34620440)
26. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-her2 monoclonal antibody in women who have her2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639-48. (Pubitemid 29415219)
27. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of her2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:719-26. (Pubitemid 34111379)
28. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses her2. N Engl J Med 2001; 344:783-92. (Pubitemid 32222155)
29. Sauter G, Lee J, Bartlett JM, et al. Guidelines for human epidermal growth factor receptor 2 testing: Biologic and methodologic considerations. J Clin Oncol 2009; 27:1323-33.
30. Perez EA, Suman VJ, Davidson NE, et al. Her2 testing by local, central, and reference laboratories in specimens from the north central cancer treatment group n9831 intergroup adjuvant trial. J Clin Oncol 2006; 24:3032-8. (Pubitemid 46638937)
31. Harris L, Fritsche H, Mennel R, et al. American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25:5287-312. (Pubitemid 350232263)
32. Nahta R, Esteva FJ. Trastuzumab: Triumphs and tribulations. Oncogene 2007; 26:3637-43. (Pubitemid 46842713)
33. Edge SB and American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th. New york; London: Springer, 2010.
34. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001; 19:980-91. (Pubitemid 32176272)
35. D'Eredita G, Giardina C, Martellotta M, et al. Prognostic factors in breast cancer: The predictive value of the nottingham prognostic index in patients with a long-term follow-up that were treated in a single institution. Eur J Cancer 2001; 37:591-6. (Pubitemid 32261016)
36. Olivotto IA, Bajdik CD, Ravdin PM, et al. Population-based validation of the prognostic model adjuvant! For early breast cancer. J Clin Oncol 2005; 23:2716-25. (Pubitemid 46179461)
37. Cufer T. Which tools can I use in daily clinical practice to improve tailoring of treatment for breast cancer? The 2007 st gallen guidelines and/or adjuvant! Online. Ann Oncol 2008; 19(Suppl 7):vii41-5.
38. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-52.
39. Teschendorff AE, Miremadi A, Pinder SE, et al. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2007; 8:R157.
40. Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: A retrospective of the last decade. J Pathol 2010; 220:263-80.
41. Farmer P, Bonnefoi H, Becette V, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005; 24:4660-71. (Pubitemid 41032603)
42. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to- mesenchymal transition and stem cell characteristics. Cancer Res 2009; 69:4116-24.
43. Herschkowitz JI, Simin K, Weigman VJ, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007; 8:R76.
44. Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006; 7:96.
45. Gusterson B. Do 'basal-like' breast cancers really exist? Nat Rev Cancer 2009; 9:128-34.
46. Lim E, Vaillant F, Wu D, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in brca1 mutation carriers. Nat Med 2009; 15:907-13.
47. Pusztai L, Mazouni C, Anderson K, et al. Molecular classification of breast cancer: Limitations and potential. Oncologist 2006; 11:868-77. (Pubitemid 44373759)
48. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27:1160-7.
49. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530-6. (Pubitemid 34130608)
50. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365:671-9. (Pubitemid 40260888)
51. Bueno-de-Mesquita JM, van Harten WH, Retel VP, et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: A prospective community-based feasibility study (raster). Lancet Oncol 2007; 8:1079-87. (Pubitemid 350182954)
52. Bueno-de-Mesquita JM, Linn SC, Keijzer R, et al. Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat 2009; 117:483-95.
53. Straver ME, Glas AM, Hannemann J, et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2010; 119:551-8.
54. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98:262-72. (Pubitemid 43264710)
55. Toussaint J, Sieuwerts AM, Haibe-Kains B, et al. Improvement of the clinical applicability of the genomic grade index through a qrt-pcr test performed on frozen and formalin-fixed paraffin-embedded tissues. BMC Genomics 2009; 10:424.
56. Chang HY, Sneddon JB, Alizadeh AA, et al. Gene expression signature of fibroblast serum response predicts human cancer progression: Similarities between tumors and wounds. PLoS Biol 2004; 2:E7.
57. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006; 355:560-9. (Pubitemid 44200649)
58. Ein-Dor L, Kela I, Getz G, et al. Outcome signature genes in breast cancer: Is there a unique set? Bioinformatics 2005; 21:171-8. (Pubitemid 40202018)
59. Farmer P, Bonnefoi H, Anderle P, et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 2009; 15:68-74.
60. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009; 9:631-43.
61. Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004; 5:607-16. (Pubitemid 38748922)
62. Reid JF, Lusa L, De Cecco L, et al. Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J Natl Cancer Inst 2005; 97:927-30. (Pubitemid 41417944)
63. Loi S, Haibe-Kains B, Desmedt C, et al. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 2008; 9:239.
64. Oh DS, Troester MA, Usary J, et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 2006; 24:1656-64. (Pubitemid 46622136)
65. Jansen MP, Foekens JA, van Staveren IL, et al. Molecular classification of tamoxifenresistant breast carcinomas by gene expression profiling. J Clin Oncol 2005; 23:732-40. (Pubitemid 46224172)
66. Akcakanat A, Zhang L, Tsavachidis S, et al. The rapamycin-regulated gene expression signature determines prognosis for breast cancer. Mol Cancer 2009; 8:75.
67. Staaf J, Ringner M, Vallon-Christersson J, et al. Identification of subtypes in human epidermal growth factor receptor 2-positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol 2010; 28:1813-20.
68. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24:3726-34. (Pubitemid 46622311)
69. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptorpositive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol 2010; 11:55-65.
70. Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A transatac study. J Clin Oncol 2010; 28:1829-34.
71. Goldstein LJ, Gray R, Badve S, et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 2008; 26:4063-71.
72. Carlson RW, Brown E, Burstein HJ, et al. Nccn task force report: Adjuvant therapy for breast cancer. J Natl Compr Canc Netw 2006; 4(Suppl 1):S1-26.
73. Tang G, Cuzick J, Wale C, et al. Recurrence risk of node-negative and er-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta-analysis approach. J Clin Oncol 2010; 28(suppl): (abstract 509).
74. Shipitsin M, Campbell LL, Argani P, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007; 11:259-73. (Pubitemid 46349843)
75. Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007; 356:217-26. (Pubitemid 46143225)
76. Borges S, Desta Z, Li L, et al. Quantitative effect of cyp2d6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006; 80:61-74. (Pubitemid 43946844)
77. Nowell S, Sweeney C, Winters M, et al. Association between sulfotransferase 1a1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J Natl Cancer Inst 2002; 94:1635-40. (Pubitemid 35378729)
78. Wang L, Ellsworth KA, Moon I, et al. Functional genetic polymorphisms in the aromatase gene cyp19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res 2010; 70:319-28.
79. Ambrosone CB, Sweeney C, Coles BF, et al. Polymorphisms in glutathione s-transferases (gstm1 and gstt1) and survival after treatment for breast cancer. Cancer Res 2001; 61:7130-5. (Pubitemid 32946505)
80. Schneider BP, Radovich M, Sledge GW, et al. Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat 2008; 111:157-63. (Pubitemid 352009224)
81. Gilmer TM, Cable L, Alligood K, et al. Impact of common epidermal growth factor receptor and her2 variants on receptor activity and inhibition by lapatinib. Cancer Res 2008; 68:571-9. (Pubitemid 351380086)
82. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in brca mutant cells as a therapeutic strategy. Nature 2005; 434:917-21. (Pubitemid 40559006)
83. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(adp-ribose) polymerase in tumors from brca mutation carriers. N Engl J Med 2009; 361:123-34.
84. O'Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of bsi-201, a poly (adp-ribose) polymerase-1 (parp1) inhibitor, in combination with gemcitabine/carboplatin (g/c) in patients with metastatic triple-negative breast cancer (tnbc): Results of a randomized phase ii trial. J Clin Oncol 2009; 27(suppl): (abstract 3).
85. Tuma RS. Parp inhibitors: Will the new class of drugs match the hype? J Natl Cancer Inst 2009; 101:1230-2.
86. Khoshnaw SM, Green AR, Powe DG, et al. Microrna involvement in the pathogenesis and management of breast cancer. J Clin Pathol 2009; 62:422-8.
87. Blenkiron C, Goldstein LD, Thorne NP, et al. Microrna expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 2007; 8:R214.
88. Foekens JA, Sieuwerts AM, Smid M, et al. Four mirnas associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci USA 2008; 105:13021-6.